CABINET Trial: Study Design and Patient Population

Video content above is prompted by the following:

The CABINET Trial Design and Significance

Key Themes:

• Trial Design:
• NCI-supported study run through the Alliance for Clinical Trials in Oncology network

• Included well-differentiated grade 1, 2, or 3 pancreatic or extrapancreatic neuroendocrine tumors

• Required disease progression after somatostatin analogue therapy and at least 1 other FDA-approved therapy

• 2:1 randomization to cabozantinib vs placebo with crossover option
• Trial Significance:
• Rigorously conducted through academic institutions and large community practices

• Particularly important for demonstrating active therapy post radioligand therapy

• Protocol modifications improved accrual rates as the trial progressed

Notable Insights:

Dr Halfdanarson emphasized that the CABINET trial provides valuable evidence for treatment options following radioligand therapy with lutetium-177 dotatate, addressing a knowledge gap in the field.